Xoma's bone marrow immunotoxin
Firm reports results of an initial clinical test of monoclonal antibody-based immunotoxin Xomazyme-Lym for treatment of graft versus host disease, a complication of bone marrow transplantation. Xoma says one patient in the study, a 10-year old girl, demonstrated reversal of GVHD after treatment with the drug. The first monoclonal antibody approved by FDA for therapeutic use, Ortho's Orthoclone OKT 3, was for reversal of actue kidney transplant rejection.
You may also be interested in...
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.
Tests used to detect cytomegalovirus in organ transplant patients may face an easier path to market under a proposed rule that the US Food and Drug Administration released on 18 September. See what the regulatory agency said about it here.
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.